BioSpace News Archive

Xenon Pharmaceuticals Inc. announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, December 4, 2019 at 3:00 pm Eastern Time.

Johnson & Johnson Consumer Inc. reaffirmed that its Johnson’s Baby Powder is safe and free of asbestos after a comprehensive investigation into the United States Food and Drug Administration’s earlier reported finding of sub-trace levels of asbestos in samples from a single bottle of Johnson’s Baby Powder.

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced that Siddharth Mittal has taken over as Chief Executive Officer & Joint Managing Director of the Company starting December 1, 2019. Mr. Mittal has been serving as Biocon’s Chief Financial Officer (CFO) since August 2014.

Eisai Co., Ltd. announced today that three oral presentations and eight poster presentations, highlighting the latest data on its Alzheimer’s disease / dementia pipeline including anti-amyloid beta (Abeta) protofibril antibody BAN2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzheimer’s disease (AD

Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Lewis Cameron as Chief Operating Officer (COO) and to the Board, effective from January 20th, 2020.

Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit

CASI Pharmaceuticals, Inc. announces that the China National Medical Product Administration, has approved the clinical trial applications for CNCT19 in relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma submitted by its partner Juventas Cell Therapy Ltd., a biopharmaceutical company focused on cell therapy.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $46.00 per share.

Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced the pricing of an offering of 3,333,334 shares of its common stock at a public offering price of $30.00 per share in an underwritten offering.

A new report urges biomedical researchers to use online web resources very carefully, taking into account their complementary benefits and weaknesses, when selecting small-molecule chemical probes to help answer their research questions.